Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A hidden-identity GoGlides receipts explainer on Sidus Space, balance sheet strength, small revenue, and dilution risk.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for Sidus Space, Inc..
OpenA hidden-identity GoGlides receipts explainer on Filtronic, profitability, cash, SpaceX orders, and customer-concentration risk.
OpenA hidden-identity GoGlides receipts explainer on Redwire's backlog, defense-UAS wins, cash flow, and dilution risk.
OpenSidus Space, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
OpenA hidden-identity GoGlides receipts explainer on Momentus, the space tow-truck idea, cash, losses, and dilution risk.
OpenAddex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAcumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
OpenTag facets appear after tag usage counts are rebuilt.